Linzagolix
Linzagolix is an oral, non-peptide GnRH antagonist in development for uterine fibroids, endometriosis, and adenomyosis. It potently inhibits gonadotropin release, as demonstrated in clinical and preclinical studies, making it a research tool for investigating hormone-dependent gynecological conditions.
Product Specifications
CAS Number
935283-04-8
Product Name Alternative
Adenomyosis, Gonadotropin releasing hormone receptor, GNRHR, GnRH Receptor, GNRH Receptor, GNRHReceptor, GnRHR, endometriosis, Inhibitor, OBE 2109, OBE2109, OBE-2109, inhibit, KLH 2109, KLH2109, KLH-2109, Linzagolix, uterine fibroids
Field of Research
Pharmacology & Drug Discovery
Purity
99.33% (May vary between batches)
Solubility
DMSO:55 mg/mL (108.18 mM)
Smiles
COc1cc (F) c (cc1OCc1c (OC) ccc (F) c1F) -n1c (=O) [nH]c2csc (C (O) =O) c2c1=O
Molecular Formula
C22H15F3N2O7S
Molecular Weight
508.42
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
